EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BMP4 and Temozolomide Synergize in the Majority of Patient-Derived Glioblastoma Cultures

Iris S C Verploegh iD, Andrea Conidi iD, Hoesna El Hassnaoui, Floor A M Verhoeven, Anne L Korporaal, Ioannis Ntafoulis, Mirjam C G N van den Hout iD, Rutger W W Brouwer iD, Martine L M Lamfers iD, Wilfred F J van IJcken iD, Danny Huylebroeck iD, Sieger Leenstra

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms251810176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Iris S C Verploegh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Bone Morphogenetic Protein 4, Temozolomide, Glioblastoma, Neoplastic Stem Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the main causes of poor prognoses in patient with glioblastoma (GBM) is drug resistance to current standard treatment, which includes chemoradiation and adjuvant temozolomide (TMZ). In addition, the concept of cancer stem cells provides new insights into therapy resistance and management also in GBM and glioblastoma stem cell-like cells (GSCs), which might contribute to therapy resistance. Bone morphogenetic protein-4 (BMP4) stimulates astroglial differentiation of GSCs and thereby reduces their self-renewal capacity. Exposure of GSCs to BMP4 may also sensitize these cells to TMZ. A recent phase I trial has shown that local delivery of BMP4 is safe, but a large variation in survival is seen in these treated patients and in features of their cultured tumors. We wanted to combine TMZ and BMP4 (TMZ + BMP4) therapy and assess the inter-tumoral variability in response to TMZ + BMP4 in patient-derived GBM cultures. A phase II trial could then benefit a larger group of patients than those treated with BMP4 only. We first show that simultaneous treatment with TMZ + BMP4 is more effective than sequential treatment. Second, when applying our optimized treatment protocol, 70% of a total of 20 GBM cultures displayed TMZ + BMP4 synergy. This combination induces cellular apoptosis and does not inhibit cell proliferation. Comparative bulk RNA-sequencing indicates that treatment with TMZ + BMP4 eventually results in decreased MAPK signaling, in line with previous evidence that increased MAPK signaling is associated with resistance to TMZ. Based on these results, we advocate further clinical trial research to test patient benefit and validate pathophysiological hypothesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Morphogenetic Protein 4TemozolomideGlioblastomaNeoplastic Stem CellsBrain NeoplasmsHumansDrug SynergismCell ProliferationTumor Cells, CulturedApoptosisFemaleMaleMiddle AgedAntineoplastic Agents, AlkylatingAgedDrug Resistance, Neoplasm

Stichwörter der Autor:innen

bone morphogenetic proteinsdrug synergyglioblastomatemozolomidetherapy

Substanzen

Bone Morphogenetic Protein 4TemozolomideBMP4 protein, humanAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Neurosurgery, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
  • Department of Cell Biology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
  • Department of Clinical Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
  • Center for Biomics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.

ORCID-Profile: Iris S C Verploegh, Andrea Conidi, Mirjam C G N van den Hout, Rutger W W Brouwer, Martine L M Lamfers, Wilfred F J van IJcken, Danny Huylebroeck

Zitieren

APA

Verploegh, I. S. C., Conidi, A., El Hassnaoui, H., Verhoeven, F. A. M., Korporaal, A. L., Ntafoulis, I., van den Hout, M. C. G. N., Brouwer, R. W. W., Lamfers, M. L. M., van IJcken, W. F. J., Huylebroeck, D., & Leenstra, S. (2024). BMP4 and Temozolomide Synergize in the Majority of Patient-Derived Glioblastoma Cultures. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251810176

Vancouver

Verploegh ISC, Conidi A, El Hassnaoui H, Verhoeven FAM, Korporaal AL, Ntafoulis I, et al. BMP4 and Temozolomide Synergize in the Majority of Patient-Derived Glioblastoma Cultures. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251810176

BibTeX
@article{Verploegh2024,
  author = {Verploegh, Iris S C and Conidi, Andrea and El Hassnaoui, Hoesna and Verhoeven, Floor A M and Korporaal, Anne L and Ntafoulis, Ioannis and van den Hout, Mirjam C G N and Brouwer, Rutger W W and Lamfers, Martine L M and van IJcken, Wilfred F J and Huylebroeck, Danny and Leenstra, Sieger},
  title = {BMP4 and Temozolomide Synergize in the Majority of Patient-Derived Glioblastoma Cultures},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms251810176}
}
Kostenlos starten →